Acronym:
MONARCC
ACTRN/NCT /ethics:
ACTRN12618000233224
Scientific title:
MONARCC: A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer.
Summary of trial and patient characteristics
| Cancer Type | Bowel and colon | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase II | Tumour Stream | Colorectal |
| Age Range | 18 years and older | Cancer Stage | Metastatic or Widespread |
| Sex | Both | Anticipated Start Date | 2018-03-30 |
| Molecular Target | Anticipated End Date | 2020-01-31 | |
| Cancer Type | Bowel and colon |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Colorectal |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2018-03-30 |
| Anticipated End Date | 2020-01-31 |
Trial Summary
This trial (MONARCC) seeks to determine what the best initial treatment is for a patient population with metastatic colorectal cancer that cannot withstand the expected side effects of the commonly used combination chemotherapy regimens.
Lay Summary
MONARCC: A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer.
Sponsor / Cooperative group
AGITG
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| The Queen Elizabeth Hospital | Pamela Cooper | pamela.cooper@sa.gov.au | 08 8222 6410 | Professor Tim Price | Recruiting |
| Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Dr Chris Karapetis | Recruiting |